Company intelligence / Profile preview

AMT Pharma

Ownership: Private
Development stage: Commercial

Overview

Mixed clinical results - AMT-101 failed in ulcerative colitis trials but showed promise in pouchitis, receiving FDA orphan-drug designation. The company has faced financial challenges, implementing significant layoffs (40% in 2022, followed by 57% in 2023) and seeking strategic alternatives.

Therapeutic areas: GastroenterologyImmunology
Modalities: Oral fusion proteins
Industry: Biotech

Partnerships

Research collaboration and license agreement with Janssen Biotech

Beyond the preview

Go deeper on AMT Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMT Pharma.

Explore the full profile